文献

J-GLOBAL ID：202202276717218416   整理番号：22A1030467

中国人成人における心血管リスク評価のための陰性リスクマーカー【JST・京大機械翻訳】

Negative Risk Markers for Cardiovascular Risk Evaluation in Chinese Adults

著者 (35件)： Bie Lizhan (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Bie Lizhan (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Niu Jingya (Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, China) ,  Wu Shujing (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Wu Shujing (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Zheng Ruizhi (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Zheng Ruizhi (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Xu Min (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Xu Min (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Lu Jieli (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Lu Jieli (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Wang Tiange (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Wang Tiange (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Zhao Zhiyun (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Zhao Zhiyun (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Wang Shuangyuan (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Wang Shuangyuan (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Lin Hong (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Lin Hong (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Dai Meng (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Dai Meng (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Zhang Di (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Zhang Di (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Chen Yuhong (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Chen Yuhong (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Bi Yufang (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Bi Yufang (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Wang Weiqing (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Wang Weiqing (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Ning Guang (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Ning Guang (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Li Mian (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Li Mian (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Xu Yu (Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China) ,  Xu Yu (Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China)
資料名： Frontiers in Cardiovascular Medicine (Web)  (Frontiers in Cardiovascular Medicine (Web))
巻： 9  ページ： 800671  発行年： 2022年 
JST資料番号： U7061A  ISSN： 2297-055X  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： スイス (CHE)  言語： 英語 (EN)

抄録/ポイント： 背景:従来の危険因子により予測される動脈硬化性心血管疾患(ASCVD)リスクは,予防治療を誘導するために使用される。著者らは,非伝統的な新興危険因子(すなわち,負のリスクマーカー)の好ましいレベルが,従来の危険因子を超えて予測されたASCVDリスクを低下できるかどうかを調査することを目的とした。【方法】≧40歳の合計7,568人の中国人成人を,2010年~2015年の間に追跡調査した。非伝統的脂質,尿中アルブミン-クレアチニン比,心電図(ECG),およびアテローム性動脈硬化症の測定値を含む陰性リスクマーカーを,全体的研究集団および中間(伝統的危険因子予測ASCVDリスク7.5%から19.9%)または高リスク(≧20%)の参加者において,予測CVDリスクをダウンシフトする能力のために,診断尤度比(DLR)および連続ネット再分類指数(NRI)を用いて評価した。結果:4.5年の追跡期間中央値の間,416人の参加者は,非致死的心筋梗塞,非致死的脳卒中および心血管死亡を含むCVDイベントを発症した。検討した陰性リスクマーカーの中で,リポ蛋白質(a)≦10パーセンタイル(5mg/dL),正常ECG,および頚動脈内膜中膜肥厚(CIMT)≦25パーセンタイル(0.5mm)は,特に高リスク参加者において,従来のCVDリスク因子のトップに関する試験前リスクの中等度のCVDリスク再分類および下方変化を与えた。DLRsは0.41,0.75および0.41であり,NRIsは高リスク参加者においてそれぞれリポ蛋白質(a),ECGおよびCIMTに対して18,22および14%であった。結論:Lipoprotein(a)≦5mg/dL,正常ECG,およびCIMT≦0.5mmは,中国人成人における予測ASCVDリスクを正しく低下させるための陰性非伝統的リスクマーカーとして使われる可能性がある。Copyright 2022 The Author(s) All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： *リスク ,  心電図 ,  脂質 ,  成人 ,  心筋梗塞 ,  心血管疾患 ,  脳卒中 ,  *人間 ,  アテローム性動脈硬化症 ,  危険因子
準シソーラス用語： 尤度比 ,  尿中アルブミン ,  *心血管リスク ,  心血管死 ,  頚動脈内膜中膜肥厚 , 【Automatic Indexing@JST】

著者キーワード (5件)： 心血管疾患 ,  負のリスクマーカー ,  リポ蛋白(a) ,  心電図 ,  頸動脈内膜中膜厚

分類 (2件)： 循環系の疾患  (GJ03000C) ,  循環系の臨床医学一般  (GJ01030V)

引用文献 (32件)：

• Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. (2020) 76:2982-3021. doi: 10.1016/j.jacc.2020.11.010
• Goff DC Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. (2014) 129:S49-73. doi: 10.1161/01.cir.0000437741.48606.98
• Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. (2016) 37:2315-81. doi: 10.1093/eurheartj/ehw106
• Navar-Boggan AM, Peterson ED, Pencina MJ, Sniderman AD. Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all. J Am Coll Cardiol. (2015) 65:1633-9. doi: 10.1016/j.jacc.2015.02.025
• Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. (2018) 71:85-94. doi: 10.1016/j.jacc.2017.10.080

タイトルに関連する用語 (6件)： 中国人 ,  成人 ,  心血管リスク ,  評価 ,  リスク ,  マーカー